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In chronic hepatitis B infection, adenine-9-fl-D- 
arabinofuranoside (ara-A) reduces, in a dose de- 
pendent fashion, the serum levels of virus DNA- 
polymerase [1-4] with an improvement in liver 
function and histology [5] and a loss of infectivity 
in some patients [4]. However this drug produces 
dose-dependent side effects [6-8] which might be 
avoided or reduced by selectively delivering ara-A 
to hepatocytes. In mice, liver targeting of ara-A 
has been obtained by conjugation with asialofetuin 
(AF) [9] or with lactosaminated serum albumin (L- 
SA) [10], two galactosyl-terminating glycoproteins 
which penetrate by a receptor-mediated endo- 
cytosis only in hepatocytes where they are digested 
in lysosomes [11-16]. AF-ara-A and L-SA-ara-A 
conjugates, administered to mice with Ectromelia 
virus-hepatitis, inhibited virus DNA synthesis in 
liver without producing significant inhibition of 
cellular DNA synthesis in intestine and bone mar- 
row [9,10]. L-SA has a definitive advantage over 
AF as hepatotropic arrier of ara-A since con- 
jugates prepared with lactosaminated homologous 
albumin are not immunogenic, at least in mice, to 
the contrary of AF conjugates which are strong 
antibody inducers [17]. Moreover as opposed to 
naturally occurring glycoproteins of human blood, 
which after desialylation are also taken up by 
hepatocytes [12], L-(human)SA (L-HSA) can easi- 
ly be obtained in the amounts required for clinical 
purposes. 
By receptor-mediated ndocytosis proteins enter 
into cells only in limited amounts; the hepatic up- 
take of AF in rats does not exceed 0.18/~g. g body 
wt -1 • min - l  [18]. In the present experiments we 
have calculated the maximal rate of hepatic uptake 
in mice of two L-HSA preparations with 22 and 40 
galactosyl residues, respectively. Moreover, we 
have determined the minimal doses of free or con- 
jugated ara-A which inhibit DNA synthesis in liver 
of Ectromelia virus-infected mice. These experi- 
ments were undertaken in order to calculate 
whether the amounts of ara-A needed to exert 
antiviral activity in chronic hepatitis B can be 
transported to hepatocytes by L-HSA. 
2. MATERIALS AND METHODS 
2.1. Tissue distribution of L-[14C]HSA 
Lactose was coupled to the c -NH 2 oflysine res- 
idues of HSA by reductive amination with 
cyanoborhydride [19,20]. The albumin concen- 
tration was determined as in [21]. The amount of 
sugar conjugated to protein was established by the 
phenol/sulfuric acid method [22] calibrated 
against galactose. In different preparations of L- 
HSA increasing amounts of lactose were coupled 
as a function of time of reaction [20,14]. Labelling 
of L22-HSA (2 x 106 dpm/mg), L40-HSA (3.7 x 
106 dpm/mg) and of non-desialylated fetuin (3 x 
106 dpm/mg) was performed with iodo[14C]acetic 
acid (Amersham, 54 mCi/mmol) as in [14], but 
using a higher concentration of iodo[laC]acetic 
acid. Female Swiss mice (25-26 g), fasted over- 
night, were injected i.v. with L22-[IaC]HSA or L40- 
[laC]HSA administered in saline (10/al/g body wt) 
at the indicated doses. After 7 min, when hydro- 
lysis of L-HSA, and consequently losses of radio- 
activity from the liver, are negligible (see table 2), 
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the animals were bled from the retro-orbital plexus 
under ether anaesthesia, nd liver, kidneys, spleen 
and a tract of the intestine (8 cm long starting from 
pylorus) were rapidly removed and homogenized 
in 4 vol (wt/vol) of water. The total radioactivity of 
plasma and homogenates as well as the radioac- 
tivity of their acid soluble fraction were measured. 
The radioactive contribution given by the plasma 
trapped in the organs was calculated and sub- 
tracted. To assess the amounts of trapped plasma, 
5 female Swiss mice (25-26 g), fasted overnight, 
were i.v. injected with 14C-labelled non-desialyl- 
ated fetuin (10/~g/g body wt in 5 ~tl saline). After 2 
min, the animals were killed and the radioactivity 
of plasma and organs was measured. Since plasma 
clearance of fetuin is very slow (unpublished ex- 
periments), it was assumed that all the radioac- 
tivity contained in the organs at 2 min was due to 
trapped plasma. It was thus calculated that 1 mg of 
liver, intestine, spleen and kidney contains respec- 
tively 0.1060 _ 0.006, 0.0192 ___ 0.006, 0.0532 _ 
0.007 and 0.1160 ___ 0.007 #1 of plasma. 
2.2. L-HSA-ara-A conjugates 
Ara-A monophosphate (ara-AMP) was coupled 
to L-HSA by the use of 1-ethyl-3-(dimethyl- 
aminopropyl)carbodiimide [10]. Knowing that the 
amount of galactosyl residues bound to albumin 
decreases during ara-AMP coupling [10], we ob- 
tained 22 and 43 galactosyl residue conjugates 
when starting from L34-HSA and L57-HSA respec- 
tively. After gel chromatography on a Sephadex 
G-100 column, equilibrated and eluted with 0.05% 
NaC1 solution, the fractions corresponding to the 
monomeric form of the conjugate (about 70% of 
the whole conjugate preparation) were pooled, di- 
alyzed against water and lyophilized. Uncon- 
jugated ara-AMP was recovered, as will be de- 
scribed elsewhere. The molar ratio sugar/albumin 
in L-HSA-ara-A conjugates was measured taking 
into consideration the contribution given by ara- 
binose in the phenol/sulphur reaction [22]. The 
molar ratio ara-A/albumin was determined spec- 
trophotometrically. 
2.3. [methyl-3 H]thymidine incorporation into DNA 
in fiver and &testine of Ectromelia virus- 
infected mice 
Mice were killed 46 h after infection with Ectro- 
melia virus (Hampstead mouse strain) (2 x 105 
p.f.u./g body wt) [23,24]. The experiments were 
performed as previously described [10] with the 
difference that 9-erythro-(2-hydroxyl-3-nonyl)- 
adenine (ENHA), ara-A (free or coupled to L- 
HSA) and [methyl-3H]thymidine were admin- 
istered 45, 30 and 15 min, respectively, before ani- 
mals were killed. 
3. RESULTS AND DISCUSSION 
L22-HSA and L40-HSA interact with the hepatic 
receptor for asialoglycoproteins; a  shown in table 
1, they competitively inhibited the blood clearance 
of [14C]AF in mice. L40-HSA exerted a higher in- 
hibition than L22-HSA, in agreement with the 
finding that the affinity in vitro of galactosylated 
albumins to the hepatocyte r ceptor increases with 
increase in the number of coupled sugar molecules 
[25]. 
Table 2 shows that doses of 2.5/tg/g body wt of 
both L22-[IaC]HSA and L40-[14C]HSA are enough 
to saturate the hepatic receptor for a 7 min period: 
by increasing the dose to 4/~g, the liver uptake of 
the two L-[14C]HSAs does not increase. At these 
doses L22-HSA penetrates almost exclusively in 
the liver, only very small quantities being taken up 
by the cells of intestine, spleen and kidney. In the 
case of L40-[14C]HSA a non-negligible amount of 
glycoconjugate is taken up also by the kidney. This 
finding (confirmed by unpublished experiments) 
indicates that L22-HSA is a better carrier than L40- 
Table 1 
Effect of L22-HSA and L40-HSA on plasma clearance of 
[14C]AF 
Exp. Compounds injected 
no. with [14C]/AF dpm/ml plasma 
1 None 19140__. 212 
2 AF 25490___ 1407 
3 L22-HSA 25120 ± 2142 
4 L40-HSA 29510 ± 3450 
Swiss female mice (25-26 g) were injected i.v. with 2 
~g/g body wt of [ 14C]AF (4.4 x 105 dpm/mg) prepared 
according to [29]. Unlabelled AF or L-HSA were ad- 
ministered simultaneously with [14C]AF at 4 ~g/g body 
wt. After 5 min animals were killed and the radioactivity 
of plasma was measured. Each entry represents the 
mean value (__. SD) of results from 2 animals 
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Table 2 
Tissue distribution of L-[ ~4C]HSA 7 min after injection 
Compound Dose (/~g/g L-HSA in tissues (ng/mg) 
injected body wt) Liver Intestine Spleen Kidney 
L-HSA in plasma Wet weight 
(~g/ml) of liver (g) 
L22-[14C]HSA 1.25 19.6_+6,48(1.3) a 0 .4_+0 0.6_+0.30 0.6_+0.22 
2.5 32.8_+2,18(1.6) 0.5_+0.10 0.7_+0.20 0.5_+0.23 
4.0 35.0_+6.38(1.4) 0.2_+0.23 0.9_+0.23 0.2_+0.23 
L~-[14C]HSA 1.25 24.8_+3.43(1.7) 0 .3_+0 0.4_+0.14 1.5_+0.28 
2.5 36.2_+3.01(1.7) 0.4_+0.10 0.4_+0.25 2.4_+0.30 
4.0 33.3_+9.66(2.2) 0.6_+0.35 1.4_+0.44 3.4_+1.45 
3.4_+0.20 1.35_+0.20 
20.7 _+ 4.98 1.15 _+ 0.09 
49.5_+5.80 1.12_+0.02 
3.2_+2.64 1.12_+0.08 
12.9_+ 1.17 1.29_+0.05 
51.8_+2.62 1.13_+0.07 
a In parenthesis the percentage ofacid soluble radioactivity over total radioactivity. 
Each entry represents he mean value (+ SD) of results from 4 animals 
Table 3 
Inhibition of DNA synthesis in liver and intestine of Ectromelia virus-infected 
mice after injection of free or conjugated ara-A 
Exp. Compound 
no. injected 
ara-A admin. Inhibition of DNA synthesis (%) 
(t~g/g body wt) Liver Intestine 
l ara-A 1 25(NS) b 31(NS) 
2 ara-A 3.5 41 (S) 62(S) 
3 ara-A 5 44(S) 61 (S) 
4 L22-HSA-ara-All 0.15(4) a 32(S) 8(NS) 
5 L22-HSA-ara-All 0.3(8) 37(S) 4(NS) 
6 L22-HSA-ara-AI i 0.3(8) 44(S) 8(NS) 
7 L43-HSA-ara-AI0 0.25(8) 41(S) 6(NS) 
a In parentheses the amount of conjugate injected (in ~tg/g body wt) 
b Results were statistically evaluated by means of Student's t-test. The dif- 
ference was considered statistically significant (S) or not significant (NS) for 
P < or > 0.05, respectively 
In each experiment 14 animals were used (7 controls; 7 injected with free or 
conjugated ara-A) 
HSA for liver targeting of drugs. Taking into ac- 
count the hepatic concentration of L-[14C]HSA at 
7 rain, the weight of liver and that of mice after a 
15 h fast (22-23 g), it can be calculated that the 
maximum amounts of Lz2-HSA and of L40-HSA 
which can enter into mouse liver are 0.24 +_ 0.01 
and 0.26 +_ 0.04/~g ° g body wt -1 • min -1, respec- 
tively. On an equimolar basis these values fit well 
with that of the maximal hepatic uptake of AF in 
rat (0.18 t~g. g body wV I , min I) [18] (Mr of AF, 
L22-HSA and L40-HSA: 45 500, 76 500 and 82 500, 
respectively). An electron microscope autoradio- 
graphic study [15] has shown that [12511AF, admin- 
istered to rats at a dose of about 4 ~g/g body wt, 
was associated almost exclusively with hepatocytes 
after 15 min. This finding together with the obser- 
vation that albumin containing 25 galactosyl resi- 
dues binds in vitro to the liver asialoglycoprotein 
receptor with an affinity similar to that of asialo- 
orosomucoid [25], (which is twice as high as that of 
AF [12]) suggests that in our experiments the up- 
take of L-[|4C]HSA by the liver took place mainly 
in hepatocytes. The hepatic receptor for galactosyl- 
terminating lycoproteins is not destroyed after 
44 
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internalization following ligand binding and un- 
occupied receptor molecules are promptly re- 
turned to the cell surface from an internal pool 
[26]. Consequently the hepatic 
tosyl-terminating glycoproteins 
with time [ 18]. 
Table 3 shows the effects of 
uptake of galac- 
remains constant 
free and coupled 
ara-A on [methyl-3H]thymidine incorporation in 
liver and intestinal DNA of mice which had been 
injected with Ectromelia virus 46 h earlier. At this 
time of infection the largest amount of thymidine 
incorporation i to liver DNA is due to virus DNA 
synthesis [27,10], most of which occurs in hepato- 
cytes [10]. Free ara-A produced a greater inhibi- 
tion of DNA synthesis in the intestine than in the 
liver; on the contrary, and in agreement with pre- 
vious results [10], inhibition of DNA synthesis by 
ara-A coupled to L22-HSA or to L43-HSA was 
higher in liver than in the intestine. Doses of con- 
jugated ara-A about 10 times lower than those of 
the free drug produced a comparable inhibition of 
DNA synthesis in liver. 
Free ara-A is given by continuous infusion in 
the treatment of chronic hepatitis B [1,2,4] as well 
as in infections caused by other DNA viruses [28], 
the dose usually being 15 mg. kg I .  12 h - I  which 
corresponds to 21 ng .g  -1 .rain - l .  Since the 
amounts of ara-A required to inhibit virus DNA 
synthesis n liver are approximately 10 times smaller 
when the drug is coupled to L-HSA (table 3), 2.1 
ng. g body w~ l • min -1 is the dose of conjugated 
ara-A which should be infused to patients with 
chronic hepatitis B. In the conjugate Lzz-HSA- 
ara-All, 2.1 ng ara-A is bound to 0.055 /.tg Lz2- 
HSA. According to the data of the present experi- 
ments L22-HSA enters into mouse liver at a rate of 
0.24 /.tg.g body wt-I/min. Therefore provided 
that human hepatocytes infected by hepatitis B 
virus have a similar capacity of taking up L22-HSA 
as do mouse hepatocytes, this carrier should be 
able to transport o such hepatocytes the dose of 
ara-A required to exert antiviral activity. 
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